Skip to main content

Open for business in the USA: Olink Proteomics unveils a new office and analysis service laboratory in the Boston area.

Press release   •   May 31, 2016 06:29 EDT

Uppsala, Sweden, May 31, 2016 – Olink Proteomics is delighted to announce the opening of new office and laboratory facilities in Watertown, Massachusetts. This heralds the establishment of the company’s first major regional organization outside of Sweden, and will support the rapidly growing business in the United States.

Olink Proteomics Inc. currently has a national sales organization with representatives covering all regions of the US, and the opening of this new regional head office and state-of-the-art analysis service facility in Boston completes the first stage in establishing a US presence. Building on the growing success of its Proseek® Multiplex platform for targeted human protein biomarker discovery and enabling of precision medicine, the new organization will support and develop the rapidly expanding US market, making this innovative precision proteomics solution available to a wider audience than ever before.

Olink Proteomics has always believed that strong, local representation in the form of a highly knowledgeable and service-minded sales organization is essential to serve its customers with the high standards that they expect. The establishment of the US operation represents the next major evolution along this path, following the expansion of the European sales force in 2015. Moreover, the new US laboratory facilities will help to meet the rapidly growing demands on the analysis service business, and provide a convenient, efficient touch-point for customers based in the United States. The new Analysis Service team in Watertown will provide the same outstanding quality standards that have been established by the current facility in Uppsala, Sweden.

“We are thrilled to be able to announce the opening of our new facilities in Watertown, and with it, the launch of a complete US organization. The United States has always been at the forefront of Olink’s strategic plans based on a rapidly growing demand from our important customers here.By establishing this new regional presence, we can now take the task of supporting our US customers and enabling them with precision proteomic solutions to take personalized medicine to the next level. The United States is the global driver of proteomics research and the journey towards precision medicine, and is therefore exactly where Olink wants to be in order to partner and inspire these important biomedical developments. I think this will prove to be a very important chapter in the overall story of our company” says Jon Heimer, President & CEO of Olink Proteomics.

If you have any questions about the US organization, please contact Jon Heimer


Product and technology information
Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules, which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective target protein. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity, enabling Proseek Multiplex to achieve a combination of high multiplexing and excellent data quality that cannot be matched using standard immunoassay techniques. An animation illustrating how the technology works and what it is used for can be viewed on our YouTube channel.

For research use only. Not for use in diagnostic procedures.

Olink Proteomics is headquartered in Uppsala, Sweden.

For more information, please visit

Proseek is a registered trademark of Olink Proteomics AB.

Comments (0)

Add comment


By submitting the comment you agree that your personal data will be processed according to Mynewsdesk's Privacy Policy.